Neuracle Science Co., Ltd.

Neuracle Genetics Inc.

Soon-gu Kwon

Dong Sik Kim

Bongcheol Kim

Juwon Shim

Jae-Keun Lee

Jong-Mook Kim

Jae Young Seong

Eun Bee Cho

Shin-Hyuk Kang

Tae Woo Kim

The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a retinopathy (e.g., diabetic retinopathy) and/or maculopathy (e.g., age-related macular degeneration) in a subject in need thereof.

Use of anti-FAM19A5 antibodies

The present disclosure provides adeno-associated vims (AAV) vectors and uses thereof. In certain embodiments, the AAV vectors comprise a nucleic acid that encodes an antagonist against a family with sequence similarity 19, member A5 (FAM19A5) protein, e.g., anti-FAM19A5 antibody, e.g., anti-FAM19A5 scFv.

Adeno-associated virus (AAV) delivery of anti-FAM19A5 antibodies

The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a glaucoma in a subject in need thereof.

Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma

The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a Kof 10 nM or less, or binds to membrane bound human FAM19A5 with a Kof 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.

Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain

The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.

Growing community of inventors

Seoul, South Korea

Soon-gu Kwon